<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631421</url>
  </required_header>
  <id_info>
    <org_study_id>140983</org_study_id>
    <nct_id>NCT02631421</nct_id>
  </id_info>
  <brief_title>Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH</brief_title>
  <official_title>Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Right ventricular (RV) failure is the predominant cause of death in pulmonary arterial
      hypertension (PAH). No RV-specific therapies are available, in part because the underlying
      mechanisms of RV dysfunction are poorly understood. Given the heart's preference for fatty
      acids (FA) as an energy source, a deeper understanding of FA metabolism may shed light on RV
      adaptation to elevated afterload in PAH. The purpose of this study is to test the hypothesis
      that defects in fatty acid metabolism are common in PAH and contribute to RV failure. The
      investigators will measure peripheral and transcardiac lipid and glucose metabolites in PAH
      patients in comparison with patients with pulmonary venous hypertension and no evidence of
      pulmonary hypertension. The investigators will also correlate metabolites with concurrent
      measurement of right ventricular function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral blood oleoylcarnitine in PAH versus control</measure>
    <time_frame>At time of clinic visit, within 24 hrs prior to right heart catheritization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change across the cardiac circulation of oleate and the glucose/lactate ratio.</measure>
    <time_frame>At time of right heart catheterization</time_frame>
    <description>The combination of these findings will indicate if there is a decreased reliance on FAO and and increased glycolysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of oleoylcarnitine, other acylcarnitines and free fatty acids with the homeostatic index of insulin resistance, tricuspid annular plane systolic excursion, and six minute walk distance</measure>
    <time_frame>At time of clinic visit, within 24hrs prior to right heart catheritization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the trans-cardiac gradient of oleate and lactate/glucose with right ventricular ejection fraction on cardiac MRI and six minute walk distance.</measure>
    <time_frame>At time of right heart catheterization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of trans-cardiac acylcarnitines</measure>
    <time_frame>At time of right heart catheterization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of trans-cardiac and trans-pulmonary glucose metabolites</measure>
    <time_frame>At time of right heart catheterization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of trans-cardiac and trans-pulmonary lipid metabolites</measure>
    <time_frame>At time of right heart catheterization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of trans-cardiac and trans-pulmonary amino acid metabolites</measure>
    <time_frame>At time of right heart catheterization</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Pulmonary Arterial Hypertension</arm_group_label>
    <description>Clinical diagnosis of pulmonary arterial hypertension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects and patients with other causes of PH</arm_group_label>
    <description>Patients referred for right heart catheterization who do not have PAH</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Sampling</intervention_name>
    <arm_group_label>Pulmonary Arterial Hypertension</arm_group_label>
    <arm_group_label>Healthy subjects and patients with other causes of PH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac MRI</intervention_name>
    <arm_group_label>Pulmonary Arterial Hypertension</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        PAH
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years old

          -  Scheduled to undergo cardiac catheterization (right ± left heart catheterization)
             and/or electrophysiology study in the VHVI cardiac catheterization laboratory
             (CCL)/electrophysiology laboratory (EP lab)

          -  Hemoglobin value ≥ 10 g/dL or hematocrit of ≥ 30% (measured on clinically-indicated
             blood draw within 30 days or a point-of-care measurement in CCL/EP Laboratory if
             clinically-indicated value is not available)

        Exclusion Criteria:

          -  Any individual that is anemic and has a hemoglobin value &lt; 10 g/dL and hematocrit of &lt;
             30% will be excluded from the study.

          -  If a physician performing the procedure believes that performing the extra steps and
             /or acquiring the additional blood samples will delay or otherwise compromise
             participants' care, he/she can abandon acquisition of those data at his/her
             discretion.

          -  Contraindication to cardiac MRI (applies only to patients undergoing CMR as part of
             this protocol).

               -  Implanted ferromagnetic material

               -  Glomerular filtration rate &lt; 60mL/min (measured on clinically-indicated blood
                  draw within 30 days of CMR or a point-of-care measurement in the CMR Laboratory
                  if clinically-indicated GFR is not available)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan Brittain, MD, MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Univerisy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evan Brittain, MD, MSCI</last_name>
    <phone>615-322-4382</phone>
    <email>evan.brittain@vanderbilt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt Univeristy</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evan Brittain, MD, MSCI</last_name>
      <email>evan.brittain@lsuhsc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2014</study_first_submitted>
  <study_first_submitted_qc>December 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Evan Brittain</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

